Faculty A-Z

Scott Edwards

Clinical Assistant Professor Oncology (Pharmaceutical Sciences) BSc., BSc., (Pharm) Memorial, Pharm.D. Washington


(709) 777-8521

Dr. H. Bliss Murphy Cancer Centre 300 Prince Phillip Dr. St. John's, NL  A1B 3V6

Dr. Scott Edwards Pharm D, MSc (Oncol) is the Clinical Oncology Pharmacy Specialist with the Cancer Care Program in St. John's, Newfoundland and Assistant Professor with Memorial University.
He completed a Bachelor of Neuroscience and Pharmacy at Memorial. He completed his Doctor of Pharmacy degree from the University of Washington. He completed a Master's degree in Oncology from Newcastle University.
He is active in research in the area of chemotherapy toxicities and supportive care.
He is passionate about teaching both undergraduate and postgraduate students.

Current Position
Clinical Pharmacy Specialist, Cancer Care Program, Eastern Health. St. John’s, NL

Clinical Assistant Professor Oncology, Faculty of Medicine and School of Pharmacy, Memorial University of Newfoundland, St. John’s, NL

Masters in Oncology, Newcastle University, Newcastle, England
Doctor of Pharmacy. University of Washington, Seattle, Washington, USA.
Bachelor of Science (Pharmacy). Memorial University of Newfoundland, St. John’s, NL
Bachelor of Science (Neuroscience). Memorial University of Newfoundland, St. John’s, NL


  • Pharmacy 5302 Special Patient Populations
  • Pharmacy 5104 Therapeutics II, Lecture - Geriatrics, Oncology
  • Pharmacy 5001 Human Toxicology, Lecture - Toxic Alcohols

Research Interests
  • Chemotherapy toxicities
  • Supportive care


Murphy L, McCarthy J, McCrate F, Laing K, Powell E, Seal MD, Edwards S. Use of bisphosphonates in metastatic breast cancer: single institution review at the Dr. H. Bliss Murphy Cancer Centre. Support Care Cancer. 2013 Jun 21(6):1557-1560

Dent S, Ammendolea C, Christofides A, Edwards S, Incekol D, Pourmirza B, Kfoury S, Poirier B. A multidisciplinary perspective on the subcutaneous administration of trastuzumab in HER2-positive breast cancer. Curr Oncol. 2019 Feb;26(1):e70-e80

Walsh F, Wall, A, Abbott R, Edwards S. The Institutional Challenges of Implementing an Oncology Therapeutic Biosimilar in a Canadian Cancer Center and the Case for a Biosimilar Pharmacist. J Oncol Pharm Practice 2020;26(4_Suppl):1.

Edwards S, Abbott R, Dranitsaris G. Patient monitoring programs in oncology pharmacy practice: A survey of oncology pharmacists in Atlantic Canada. J Oncol Pharm Pract. 2019 Jun;25(4):891-895

Edwards S. Biosimilars: The role of the pharmacist. Biosimilars in Oncology June 2018

Chia S, Gandhi S, Joy AA, Edwards S, Gorr M, Hopkins S, Kondejewski J, Ayoub JP, Califaretti N, Rayson D, Dent SF. Novel agents and associated toxicities of inhibitors of the pi3k/Akt/mtor pathway for the treatment of breast cancer. Curr Oncol. 2015 Feb;22(1):33-48.

Kanji S, Hayes M, Ling A, Shamseer L, Chant C, Edwards DJ, Edwards S, Ensom MH, Foster DR, Hardy B, Kiser TH, la Porte C, Roberts JA, Shulman R, Walker S, Zelenitsky S, Moher D. Reporting Guidelines for Clinical Pharmacokinetic Studies: The ClinPK Statement. Clin Pharmacokinet. 2015 Jul;54(7):783-95.

Edwards SJ, Abbott R, Edwards J, LeBlanc M, Dranitsaris G, Donnan J, Laing K, Whelan MA, MacKinnon NJ. Outcomes assessment of a pharmacist-directed seamless care program in an ambulatory oncology clinic. J Pharm Pract. 2014 Feb;27(1):46-52.

Abbott R, Edwards S, Whelan M, Edwards J, Dranitsaris G. Are community pharmacists equipped to ensure the safe use of oral anticancer therapy in the community setting? Results of a cross-country survey of community pharmacists in Canada. J Oncol Pharm Pract. 2014 Feb;20(1):29-39.

Noonan, K., McCarthy, J., Powell, E., Laing, K., Edwards, S., McCrate, F. A population-based analysis of patients with early-stage HER 2-positive breast cancer in Newfoundland and Labrador. Oncology Exchange Volume 11 (4),2012
Dranitsaris G, Edwards S, Edwards J, Leblanc M, Abbott R. Bevacizumab in combination with FOLFIRI chemotherapy in patients with metastatic colorectal cancer: an assessment of safety and efficacy in the province of Newfoundland and Labrador. Curr Oncol. 2010;17(5):12-16.

Abbott R, Edwards S, Edwards J, Dranitsaris G. Oral anti-cancer agents in the community setting: A survey of pharmacists in Newfoundland and Labrador. CPJ Volume 144, Number 5, September/October 2011.

Edwards J, Edwards S, Saltman D. The Role of the Nurse Practitioner and Clinical Pharmacist in collaborative patient care and drug therapy management in Canadian cancer centers. Report card on cancer in Canada, 2010–11

Guidelines/National Working Groups

Advisory Committee to guide the development of the Massive Open Online Course (MOOC) on biologics and biosimilars, The University of Toronto, Leslie Dan Faculty of Pharmacy and Ontario Health (Cancer Care Ontario) 2020-2023.
Pan-Canadian Oncology Biosimilars Education Working Group, Cancer Care Ontario 2020.

Febrile Neutropenia G-CSF Prophylaxis Working Group Members for Cancer Care Ontario GCSF Recommendations 2016.

Eastern health Allied Health Professional Practice
Clinician of the Year
Accreditation Canada Leading Practice Award
Oncology Pharmacy toxicity assessments for adjuvant breast cancer patients
Named to the top 100 Pharmacists in 100 years (1910 to 2010) for Newfoundland 2010
Canadian Society of Hospital Pharmacists (NL Branch)
Leadership in Pharmacy Practice Award
Award Winning Poster - Pharmacy Practice
National Oncology Pharmacy Symposium